Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Lynch is active.

Publication


Featured researches published by Michael Lynch.


Science | 1991

Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n

Eric J. Kremer; M. Pritchard; Michael Lynch; Sui Yu; K. Holman; Elizabeth Baker; Stephen T. Warren; D Schlessinger; Grant R. Sutherland; Robert I. Richards

The sequence of a Pst I restriction fragment was determined that demonstrate instability in fragile X syndrome pedigrees. The region of instability was localized to a trinucleotide repeat p(CCG)n. The sequence flanking this repeat were identical in normal and affected individuals. The breakpoints in two somatic cell hybrids constructed to break at the fragile site also mapped to this repeat sequence. The repeat exhibits instability both when cloned in a nonhomologous host and after amplification by the polymerase chain reaction. These results suggest variation in the trinucleotide repeat copy number as the molecular basis for the instability and possibly the fragile site. This would account for the observed properties of this region in vivo and in vitro.


Science | 1991

Fragile X genotype characterized by an unstable region of DNA

Sui Yu; M. Pritchard; Eric J. Kremer; Michael Lynch; J Nancarrow; Elizabeth Baker; K. Holman; John C. Mulley; Stephen T. Warren; David Schlessinger

DNA sequences have been located at the fragile X site by in situ hybridization and by the mapping of breakpoints in two somatic cell hybrids that were constructed to break at the fragile site. These hybrids were found to have breakpoints in a common 5-kilobase Eco RI restriction fragment. When this fragment was used as a probe on the chromosomal DNA of normal and fragile X genotype individuals, alterations in the mobility of the sequences detected by the probe were found only in fragile X genotype DNA. These sequences were of an increased size in all fragile X individuals and varied within families, indicating that the region was unstable. This probe provides a means with which to analyze fragile X pedigrees and is a diagnostic reagent for the fragile X genotype.


Journal of Medical Genetics | 1991

Fragile X syndrome: genetic localisation by linkage mapping of two microsatellite repeats FRAXAC1 and FRAXAC2 which immediately flank the fragile site.

Robert I. Richards; K. Holman; H Kozman; Eric J. Kremer; Michael Lynch; M. Pritchard; Sui Yu; John C. Mulley; G.R. Sutherland

We report the genetic localisation of the fragile site at Xq27.3 associated with fragile X syndrome. The position of the fragile site within the multipoint linkage map was determined using two polymorphic microsatellite AC repeat markers FRAXAC1 and FRAXAC2. These markers were physically located within 10 kilobases and on either side of the p(CCG)n repeat responsible for the fragile site. FRAXAC1 has five alleles with heterozygosity of 44% and is in strong linkage disequilibrium with FRAXAC2 which has eight alleles and a heterozygosity of 71%. No recombination was observed either between these markers in 40 normal CEPH pedigrees or with the fragile X in affected pedigrees. These markers provide the means for accurate diagnosis of the fragile X genotype in families by rapid polymerase chain reaction analysis and were used to position the fragile X within the multipoint map of the X chromosome to a position 3.7 cM distal to DXS297 and 1.2 cM proximal to DXS296.


Journal of Medical Genetics | 1999

CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia

Anna Ruiz; Susana Puig; Josep Malvehy; Conxi Lázaro; Michael Lynch; Anna M Gimenez-Arnau; Lluís Puig; Julian Sánchez-Conejo; Xavier Estivill; Teresa Castel

The CDKN2A gene has been implicated in cutaneous malignant melanoma (CMM) in about 40% of families with linkage to chromosome 9p21, while a small proportion of families have mutations in the CDK4 gene. In order to estimate the importance of these genes in the predisposition to CMM in Spanish families and patients we have analysed, by SSCA, a total of 56 subjects belonging to 34 CMM families, and nine patients with multiple CMM and other neoplasia. We have detected germline CDKN2A mutations in six out of the 34 families (17%). A frameshift mutation (358delG) and four missense mutations (G59V, G101W (two cases), D84Y, and R87W) were identified. Five CMM patients from different families (14%) carried the A148T variant, which is known not to affect p16 activity. No mutations were detected in the patients with multiple CMM or other neoplasms. We have not found mutations either in exon 1β of the CDKN2A gene or in exon 2A of CDK4. Linkage analysis of the 9p21 region showed exclusion for one of the families for CMM and for four families for CMM/dysplastic naevi. This study indicates a small role for CDKN2A in Spanish CMM families and suggests that other genes are also responsible for CMM predisposition.


Human Genetics | 1997

Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene

Susana Puig; Anna Ruiz; Teresa Castel; Victor Volpini; Josep Malvehy; Francesc Cardellach; Michael Lynch; Jose M. Mascaro; Xavier Estivill

Abstract Genetic predisposition plays an important role in the development of nearly 10% of cases of cutaneous malignant melanoma (CMM). The CDKN2A gene has been described as responsible for melanoma susceptibility in a proportion of families with CMM linked to 9p. CDKN2A encodes a cyclin-dependent kinase inhibitor also implicated in the carcinogenesis of several sporadic tumors. Even though the incidence of other cancers is higher in CMM families, pancreatic adenocarcinoma is the only other well demonstrated cancer associated with CDKN2A mutations in some CMM pedigrees. We describe a family with four cases of CMM, eight patients affected by other cancers, and nine patients affected by dysplastic nevus (DN) syndrome. A CDKN2A frameshift mutation (358delG) was present in all the CMM patients, in at least three of the patients with other cancers (CDKN2A status is unknown in four patients), and in only two of the DN patients (CDKN2A status is unknown in one patient). An absence of linkage between chromosome 9p markers and the 358delG CDKN2A mutation and DN was detected, indicating genetic heterogeneity for DN and CMM in this family. The study strongly suggests that CDKN2A mutations are involved not only in the predisposition to CMM but also to several other types of cancer.


International Journal of Cancer | 1998

Retention of the CDKN2A locus and low frequency of point mutations in primary and metastasic cutaneous malignant melanoma

Anna Ruiz; Susana Puig; Michael Lynch; Teresa Castel; Xavier Estivill

CDKN2A has been found mutated in melanoma families which show linkage to chromosome 9p21. In contrast, a low mutation rate has been found in melanomas, suggesting that CDKN2A might not be the first target for mutation in the development of this type of tumour. To elucidate the role of the CDKN2A gene and its alternative transcript p19ARF in the development of cutaneous malignant melanoma (CMM) we have analyzed 48 primary and metastasic CMM tumours for mutations and for loss of heterozygosity (LOH). Only one point mutation was detected (2%), while hemizygous deletions were identified in 20% of these tumours. Retention of the CDKN2A locus was found in 10 (47%) tumours with deletions at one or both sides of CDKN2A, suggesting that loss of this gene is not involved in CMM‐tumour initiation and that another tumour‐suppressor gene involved in melanoma is located at 9p21. Int. J. Cancer 76:312–316, 1998.© 1998 Wiley‐Liss, Inc.


The Lancet | 1991

Hereditary unstable DNA : a new explanation for some old genetic questions ?

G.R. Sutherland; Eric J. Kremer; Michael Lynch; M. Pritchard; Sui Yu; Robert I. Richards; Eric Haan

Fragile X syndrome, associated with the fragile X chromosome, is the most common cause of familial mental retardation. The condition is characterised by a heritable DNA sequence that consists of an abnormal number of CCG repeats, and which is unstable in both mitosis and meiosis. We suggest that such heritable unstable DNA sequences could be present in other parts of the genome and that these might explain a number of genetic events that are not well understood in terms of classic genetic mechanisms. Such poorly explained observations include anticipation, incomplete penetrance, variable expression, and possibly imprinting, variegation, and multifactorial inheritance.


Human Genetics | 1992

The interleukin-7 receptor gene is at 5pl3

Michael Lynch; Elizabeth Baker; Linda S. Park; Grant R. Sutherland; Ray G. Goodwin

SummaryA DNA probe for the interleukin-7 receptor gene was used for in situ hybridisation and Southern blot analysis of a series of rodent-human hybrid cell lines. The IL-7 receptor gene maps to 5p13.


American Journal of Human Genetics | 1992

Fragile-X syndrome: Unique genetics of the heritable unstable element

Sui Yu; John C. Mulley; D. Loesch; Gillian Turner; Andrew Donnelly; Agi K. Gedeon; D. Hillen; Eric J. Kremer; Michael Lynch; M. Pritchard; G.R. Sutherland; Robert I. Richards


American Journal of Human Genetics | 1995

Chromosome 9p deletions in cutaneous malignant melanoma tumors: The minimal deleted region involves markers outside the p16 (CDKN2) gene

Susana Puig; Anna Ruiz; Conxi Lázaro; Teresa Castel; Michael Lynch; Josep Palou; Antonio Vilalta; Jean Weissenbach; J.M. Mascaró; Xavier Estivill

Collaboration


Dive into the Michael Lynch's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

M. Pritchard

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Sui Yu

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Eric J. Kremer

University of Montpellier

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Elizabeth Baker

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

G.R. Sutherland

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Susana Puig

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge